The Synthetic Collagen-Binding Peptide NIPEP-OSS Delays Mouse Myeloma Progression
Multiple myeloma (MM) is the second most common hematological malignancy. It is a clonal B-cell disorder characterized by the proliferation of malignant plasma cells in the bone marrow, the presence of monoclonal serum immunoglobulin, and osteolytic lesions. An increasing amount of evidence shows th...
Main Authors: | Syed Hassan Mehdi, Austin C. Gentry, Jue-Yeon Lee, Chong-Pyoung Chung, Donghoon Yoon |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/9/2473 |
Similar Items
-
Myeloma Bone Disease: The Osteoblast in the Spotlight
by: Rebecca E. Andrews, et al.
Published: (2021-09-01) -
Preventing osteolytic lesions and osteomyelitis in multiple myeloma
by: Aiken Dao, et al.
Published: (2022-12-01) -
Myeloma Bone Disease: A Comprehensive Review
by: Shiva Kumar Reddy Mukkamalla, et al.
Published: (2021-06-01) -
Pathophysiology and therapeutic advances in myeloma bone disease
by: Fujing Zhang, et al.
Published: (2022-12-01) -
Multiple myeloma presenting with coexisting severe marrow hypoplasia
by: Medhi K, et al.
Published: (2008-10-01)